Display 4-1: Therapies that Disqualified Patients as Responders

6/4/02


Click here to start


Table of Contents

Display 4-1: Therapies that Disqualified Patients as Responders

Display 4-14: Proportions of Patients Responding in Courses 1 and 2 of Study 711

Display 4-15: Study 711 Proportion of Patients Achieving PASI 75 by Course

Immunizations Coincided With Maximal CD4+ Memory T-Cell Reduction

Percentage of Patients With Anti-?X174 IgG ?30% of Total Anti-?X174 Response*

Squamous Cell Carcinoma of Skin by Course of Alefacept

Incidence of Injection Site Reactions

Injection Site Reactions by Severity

Malignancy Rates: Invasive Squamous Cell Cancers

PASI 75 at 2 Weeks After Last Dose by Quartiles of Weight

Baseline Characteristics of Patients Who Developed SCC or BCC

Mean EAUC CD4+ Memory by Weight Quartile

Efficacy Summary: IV vs IM

DTH Response Converting from Positive to Negative

DTH Response Converting from Positive to Negative

Influence of Concomitant Medications on the Primary Endpoint

PPT Slide

Estimated Incidence of Serious Adverse Events

Changes in Lesional Skin: Histologic Responders vs Nonresponders

Effect of Alefacept on Circulating CD4+ T-Cell Subsets*

Incidence of B Cell Lymphoma in Nonhuman Primates

Author: Steven Ertel